IQVIA’s Cynthia Verst Honored on 2019 PharmaVOICE 100 List
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV) today announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation,…
Pharmaceuticals, Biotechnology and Life Sciences
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV) today announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation,…
Final study results accepted for “Late Breaking Presentation” on October 16, 2019 TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced…
ALAMEDA, Calif.–(BUSINESS WIRE)–$BTX #AMD—BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet…
LEXINGTON, Mass.–(BUSINESS WIRE)–$ALDX—Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve…
$33.0M in Rubraca® (rucaparib) net product revenue for Q2 2019 compared to $23.8M for Q2 2018 U.S. sales increased 3%…
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of…
Industry veteran brings extensive financial and public biotechnology company experience WATERTOWN, Mass.–(BUSINESS WIRE)–Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing…
Enrollment Initiated in Phase 2 Trial Cohort Evaluating SY-1425 and Azacitidine in Genomically Defined Patients with Relapsed or Refractory Acute…
Announced completion of enrollment in Pfizer’s Phase 3 clinical trial evaluating rivipansel, the Company’s lead investigational drug candidate, in sickle…
– Company Continues to Expand its Gene Therapy Portfolio with the Addition of miniUSH2A Program – – Company to Host…